ACT Brief: AI-Driven Patient Matching, Clinical Ops Tensions, and Oral COVID Prevention Approval

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

• In part one of a post-SCOPE X interview, Liz Beatty, co-founder and chief strategy officer at Inato, explained how AI is replacing unreliable feasibility estimates with precise, real-time patient matching. The shift reduces non-enrolling sites and screen failure rates by giving sponsors accurate visibility into patient populations before site selection and protocol finalization.
• In a new column, Ken Getz identified three primary tensions transforming clinical operations: compliance-oriented culture versus critical thinking, collecting rich datasets versus essential decision-grade data, and simplifying protocol design while enabling fit-for-purpose approaches. ICH E6(R3) provides a framework legitimizing this transformation by emphasizing quality-by-design, risk proportionality, and stakeholder centricity over prescriptive compliance.
• The FDA has approved Xocova as the first oral post-exposure COVID-19 prevention therapy, based on Phase III data showing 67% risk reduction in developing symptomatic COVID-19 within 10 days of exposure. The five-day oral regimen expands antiviral strategies beyond treatment into prevention and addresses estimated 3.8-12.4 million US cases annually.

That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.